TwinStrand Biosciences Enters Agreement With Exact Sciences To Exclusively License Its Patent Estate In The Cell Free Nucleic Acid Sequencing Space
Portfolio Pulse from Benzinga Newsdesk
TwinStrand Biosciences has entered into an agreement with Exact Sciences to exclusively license its patent estate in the cell-free nucleic acid sequencing space. The license pertains to TwinStrand's Duplex Sequencing® error-correction technology, which significantly enhances the accuracy of next-generation sequencing.
July 31, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences has secured an exclusive license for TwinStrand Biosciences' Duplex Sequencing® technology, which enhances sequencing accuracy by 10,000 times. This partnership could significantly improve Exact Sciences' capabilities in detecting ultra-low frequency mutations.
The exclusive license of TwinStrand's advanced sequencing technology to Exact Sciences is likely to enhance Exact Sciences' product offerings and competitive edge in the genomics space. This could lead to increased demand for their services and potentially higher revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100